Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China

View Full Paper
Ask AI
Bookmark
Share

Authors

WWWei WangRSRuiyang SunQZQingyuan Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows Pola-R-CHP regimen achieves high overall response rates in newly diagnosed DLBCL, suggesting robust clinical efficacy and safety.

Key Points

  • 85.42% overall response rate observed among patients receiving Pola-R-CHP treatment.
  • Subgroup analyses indicate comparable progression-free survival rates for patients with and without bulky disease.
  • Assessment of patient records across 10 medical centers in Northeast China over multiple months revealed significant findings.
  • Pola-R-CHP shows promise as a first-line treatment option, though larger studies are needed for validation.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2a9https://doi.org/10.1182/blood-2025-7211
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China2025
  2. 2First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis2025
  3. 3Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025
  4. 4Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  5. 5The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025